Calming an overactive immune system with special cells
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a new type of cell therapy made from a patient's own white blood cells (called lymphocytes) that are designed to help control the immune system. The goal is to reduce inflammation and symptoms in people with hard-to-treat rheumatoid arthritis or a severe form of scleroderma (dcSSc).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have hard-to-treat rheumatoid arthritis or severe scleroderma with skin and lung involvement.
- Your disease is still active despite trying other treatments.
- You do not have any other major health conditions or infections like hepatitis or HIV.
- You have not had a previous cell therapy or certain other experimental treatments.
- You are willing to use effective birth control and to be followed for 15 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called BAFF CAR-T cells (LMY-922) for people with severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, or systemic sclerosis that have not improved with standard therapies. The treatment uses your own immune cells, modified to target and help calm the overactive immune response causing your disease. It aims to reduce symptoms and possibly provide long-term improvement.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial tests a new treatment called CAR-T cell therapy for people with severe autoimmune rheumatic diseases that have not improved with other treatments. The therapy uses your own immune cells, which are modified in a lab to attack the cells causing the disease, potentially reducing symptoms and improving quality of life.
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
This trial tests a new treatment called OL-CD19-GDT for people with systemic sclerosis or Sjögren's syndrome that hasn't responded to standard therapies. It aims to see if the treatment is safe and might help control the disease.
This trial tests a new CAR-T cell therapy called relmacabtagene autoleucel for people with diffuse systemic sclerosis (scleroderma) that is not responding to standard treatments. The goal is to see if this therapy can help control the disease.
Hear when a new Diffuse Cutaneous Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.